Infinity Pharmaceuticals Inc (INFI) ニュース

Form 8-K - Current report

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Form 8-K - Current report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Infinity Pharmaceuticals Announces Value Preservation and Maximization Plan

Infinity Pharmaceuticals, Inc. (Nasdaq: INFI) (“Infinity” or the “Company”), a clinical-stage biotechnology company developing eganelisib, a...

Form 8-K - Current report

Infinity Pharmaceuticals Announces Termination of Merger Agreement with MEI Pharma

Eganelisib Remains Primary Value Driver for Infinity Infinity to Explore Strategic Alternatives to Maximize Value for Stockholders Infinity...

Form 8-K - Current report

Infinity Pharmaceuticals Announces Stockholder Approval of Merger with MEI Pharma

Infinity Pharmaceuticals, Inc. (Nasdaq: INFI) (“Infinity”), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral...

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Infinity Pharmaceuticals Provides Additional Information on MARIO-8 Study Evaluating Eganelisib in Combination with the PD-1 Targeted Checkpoint Inhibitor Pembrolizumab (KEYTRUDA®) in Patients with Squamous Cell Cancer of the Head and Neck (SCCHN)

Infinity Pharmaceuticals, Inc. (Nasdaq: INFI) (“Infinity”), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral...

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material